Author Correction: ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2023-05-01
|
| Series: | Communications Medicine |
| Online Access: | https://doi.org/10.1038/s43856-023-00290-0 |
| _version_ | 1797831942991773696 |
|---|---|
| author | Rodney P. Rocconi Laura Stanbery Min Tang Luciana Madeira da Silva Adam Walter Bradley J. Monk Thomas J. Herzog Robert L. Coleman Luisa Manning Gladice Wallraven Staci Horvath Ernest Bognar Neil Senzer Scott Brun John Nemunaitis |
| author_facet | Rodney P. Rocconi Laura Stanbery Min Tang Luciana Madeira da Silva Adam Walter Bradley J. Monk Thomas J. Herzog Robert L. Coleman Luisa Manning Gladice Wallraven Staci Horvath Ernest Bognar Neil Senzer Scott Brun John Nemunaitis |
| author_sort | Rodney P. Rocconi |
| collection | DOAJ |
| first_indexed | 2024-04-09T13:59:46Z |
| format | Article |
| id | doaj.art-3b116a0694f44c8587eec04fd9d3ea73 |
| institution | Directory Open Access Journal |
| issn | 2730-664X |
| language | English |
| last_indexed | 2024-04-09T13:59:46Z |
| publishDate | 2023-05-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Communications Medicine |
| spelling | doaj.art-3b116a0694f44c8587eec04fd9d3ea732023-05-07T11:22:00ZengNature PortfolioCommunications Medicine2730-664X2023-05-01311110.1038/s43856-023-00290-0Author Correction: ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancerRodney P. Rocconi0Laura Stanbery1Min Tang2Luciana Madeira da Silva3Adam Walter4Bradley J. Monk5Thomas J. Herzog6Robert L. Coleman7Luisa Manning8Gladice Wallraven9Staci Horvath10Ernest Bognar11Neil Senzer12Scott Brun13John Nemunaitis14University of Alabama at Birmingham, Department of Obstetrics and Gynecology, Division of Gynecologic OncologyGradalis, IncStat-Beyond ConsultingMitchell Cancer Institute, Division of Gynecologic Oncology, University of South AlabamaGradalis, IncArizona Oncology, (US Oncology Network), University of Arizona, Creighton UniversityUniversity of Cincinnati Cancer CenterUS Oncology ResearchGradalis, IncGradalis, IncGradalis, IncGradalis, IncGradalis, IncGold Mast Consulting, LLCGradalis, Inchttps://doi.org/10.1038/s43856-023-00290-0 |
| spellingShingle | Rodney P. Rocconi Laura Stanbery Min Tang Luciana Madeira da Silva Adam Walter Bradley J. Monk Thomas J. Herzog Robert L. Coleman Luisa Manning Gladice Wallraven Staci Horvath Ernest Bognar Neil Senzer Scott Brun John Nemunaitis Author Correction: ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer Communications Medicine |
| title | Author Correction: ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer |
| title_full | Author Correction: ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer |
| title_fullStr | Author Correction: ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer |
| title_full_unstemmed | Author Correction: ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer |
| title_short | Author Correction: ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer |
| title_sort | author correction entpd1 cd39 as a predictive marker of treatment response to gemogenovatucel t as maintenance therapy in newly diagnosed ovarian cancer |
| url | https://doi.org/10.1038/s43856-023-00290-0 |
| work_keys_str_mv | AT rodneyprocconi authorcorrectionentpd1cd39asapredictivemarkeroftreatmentresponsetogemogenovatuceltasmaintenancetherapyinnewlydiagnosedovariancancer AT laurastanbery authorcorrectionentpd1cd39asapredictivemarkeroftreatmentresponsetogemogenovatuceltasmaintenancetherapyinnewlydiagnosedovariancancer AT mintang authorcorrectionentpd1cd39asapredictivemarkeroftreatmentresponsetogemogenovatuceltasmaintenancetherapyinnewlydiagnosedovariancancer AT lucianamadeiradasilva authorcorrectionentpd1cd39asapredictivemarkeroftreatmentresponsetogemogenovatuceltasmaintenancetherapyinnewlydiagnosedovariancancer AT adamwalter authorcorrectionentpd1cd39asapredictivemarkeroftreatmentresponsetogemogenovatuceltasmaintenancetherapyinnewlydiagnosedovariancancer AT bradleyjmonk authorcorrectionentpd1cd39asapredictivemarkeroftreatmentresponsetogemogenovatuceltasmaintenancetherapyinnewlydiagnosedovariancancer AT thomasjherzog authorcorrectionentpd1cd39asapredictivemarkeroftreatmentresponsetogemogenovatuceltasmaintenancetherapyinnewlydiagnosedovariancancer AT robertlcoleman authorcorrectionentpd1cd39asapredictivemarkeroftreatmentresponsetogemogenovatuceltasmaintenancetherapyinnewlydiagnosedovariancancer AT luisamanning authorcorrectionentpd1cd39asapredictivemarkeroftreatmentresponsetogemogenovatuceltasmaintenancetherapyinnewlydiagnosedovariancancer AT gladicewallraven authorcorrectionentpd1cd39asapredictivemarkeroftreatmentresponsetogemogenovatuceltasmaintenancetherapyinnewlydiagnosedovariancancer AT stacihorvath authorcorrectionentpd1cd39asapredictivemarkeroftreatmentresponsetogemogenovatuceltasmaintenancetherapyinnewlydiagnosedovariancancer AT ernestbognar authorcorrectionentpd1cd39asapredictivemarkeroftreatmentresponsetogemogenovatuceltasmaintenancetherapyinnewlydiagnosedovariancancer AT neilsenzer authorcorrectionentpd1cd39asapredictivemarkeroftreatmentresponsetogemogenovatuceltasmaintenancetherapyinnewlydiagnosedovariancancer AT scottbrun authorcorrectionentpd1cd39asapredictivemarkeroftreatmentresponsetogemogenovatuceltasmaintenancetherapyinnewlydiagnosedovariancancer AT johnnemunaitis authorcorrectionentpd1cd39asapredictivemarkeroftreatmentresponsetogemogenovatuceltasmaintenancetherapyinnewlydiagnosedovariancancer |